Pfizer May 2026: The Monthly GLP-1 Shot in Phase 2b. What the Data Show

Anyone who has followed the GLP-1 wave of the last few years knows the pattern: semaglutide weekly, tirzepatide weekly, plus, since January 2026, the first oral 25 mg options. In February and May 2026, Pfizer followed up with Phase 2b data on an ultra-long-acting GLP-1 receptor agonist that for the first time puts a serious monthly dose on the table. The data come from the program around the compound PF'3944 (also known as PF-08653944 or under its Metsera codename MET-097i), which Pfizer integrated into its own obesity portfolio at the end of 2025 through the 10 billion dollar Metsera acquisition.

This article puts into context what the numbers actually say, how they compare to semaglutide, tirzepatide, and retatrutide, and what monthly dosing means for adherence, market structure, and for microdose users who currently work with weekly research protocols.

Disclaimer: This article is for informational purposes only and does not constitute investment, legal, or medical advice. PF'3944 is not approved and not intended for human use. All substances offered at PeptidesDirect are sold exclusively for research purposes. Always check the legal and regulatory status in your country.

The study: design and subjects

Pfizer's Phase 2b study (listing as of 4 February 2026) tested PF'3944 in a randomized, placebo-controlled, double-blind design in 268 adult subjects with obesity or overweight without type 2 diabetes. The study duration is set to 64 weeks; the topline results reported in February and the follow-up analyses presented in May 2026 refer to the primary endpoint at week 28. The detailed data will be presented by Pfizer and Metsera scientists on 6 June 2026 at the 86th Scientific Sessions of the American Diabetes Association in Chicago.

The study design is unusual by GLP-1 standards because it uses a two-stage logic:

1. Titration and weekly dosing through week 12. Subjects start, as with classic GLP-1 protocols, with weekly up-titration. This serves tolerability and the build-up of a stable plasma level.
2. Switch to monthly maintenance dose from week 12. From this point, subjects receive a single injection per month. The explicit question was whether weight loss continues after switching from weekly to monthly, or whether a plateau sets in.

Three treatment arms were compared against placebo:

Arm	Monthly maintenance dose
Low dose	3.2 mg/month
Medium dose	4.8 mg/month
Placebo	-
Planned for Phase 3	9.6 mg/month (not included in Phase 2b)

The 9.6 mg dose planned for Phase 3 is thus twice as high as the highest dose tested in Phase 2b, which significantly raises expectations for final efficacy, provided safety holds up.

What Phase 2b showed

In the completer analysis at week 28, the two dose arms delivered:

• 3.2 mg/month: about 10 percentage points of placebo-adjusted weight loss
• 4.8 mg/month: about 12.3 percentage points of placebo-adjusted weight loss

In the more conservative intent-to-treat analysis, which includes all randomized subjects regardless of treatment discontinuation, the values were roughly 8 and 11 percentage points placebo-adjusted. An earlier run-in conducted as part of the Metsera development showed up to 14 percent placebo-adjusted difference at higher doses. The latter is one of the reasons Pfizer is going up to 9.6 mg in Phase 3.

More important than the isolated numbers is the shape of the curve. After the switch from weekly to monthly dosing at week 12, Pfizer observed no plateau, but a continued, linear weight loss through week 28. That is the real validity proof for the monthly shot concept: the pharmacokinetics carry a stable active level across the entire four-week interval.

Mechanism: why monthly is possible at all

Semaglutide is dosed weekly because its half-life is around one week. Tirzepatide is in a similar range. For reliable monthly dosing, the half-life has to be extended three- to four-fold without compromising efficacy or safety. With PF'3944, this is achieved via a technically optimized albumin-binding construct that massively slows renal clearance while largely preventing enzymatic degradation by DPP-4. Pfizer has not yet disclosed the exact design in detail, but the mechanism class is well known from insulin and hormone research.

In practical terms, this means: PF'3944 is not simply semaglutide in a different carrier system. The molecular structure is designed from the ground up for a flat, long pharmacokinetic profile. Precisely this flatness explains why the GI side effects, namely nausea, vomiting, and diarrhea, remained predominantly mild or moderate in the study: the plasma concentration does not rise as steeply after injection as with classic weekly-depot GLP-1s.

Safety profile

According to the data reported in February and May 2026, the safety profile is consistent with the GLP-1 class. Specifically:

• Predominantly mild to moderate gastrointestinal events (nausea, vomiting, diarrhea).
• In no dose arm was more than a single case of severe nausea or severe vomiting observed.
• No case of severe diarrhea.
• 10 subjects discontinued due to side effects. In the Phase 2b population this corresponds to about 10 percent, which is above the 6 percent discontinuation rate Lilly reported for tirzepatide in the Phase 3 SURMOUNT series, but within the range of earlier Phase 2 data for semaglutide.
• No signals published so far for pancreatitis, thyroid tumors, or hepatic abnormalities in Phase 2b. Such events are statistically hard to detect anyway in Phase 2 populations of 268 subjects.

For the assessment of monthly dosing, it is particularly relevant that the single high injection volume did not trigger unusual local or systemic peak reactions, as far as can be seen from the topline data. Detailed safety data are expected with the ADA presentation on 6 June 2026.

Positioning in the 2026 GLP-1 landscape

To give the numbers a frame of reference, here is the direct comparison to the current landscape. The values come from the respective pivotal trials (STEP-1, SURMOUNT-1, TRIUMPH-1) and are not placebo-adjusted but reported as absolute mean weight loss after 68 to 72 weeks.

Substance	Dose	Study	Mean weight loss
Semaglutide	2.4 mg weekly (s.c.)	STEP-1 (68 wks)	-14.9 %
Semaglutide oral	25 mg daily	OASIS-4 (68 wks)	-13.6 %
Tirzepatide	15 mg weekly	SURMOUNT-1 (72 wks)	-20.9 %
Retatrutide	12 mg weekly	TRIUMPH-1 (48 wks)	-24.2 %
Orforglipron (Foundayo)	oral, daily	ATTAIN-1 (72 wks)	-13.2 %
PF'3944	4.8 mg monthly	Phase 2b (28 wks)	placebo-adjusted 12.3 pp

The numbers are not directly comparable because PF'3944 was evaluated at 28 instead of 68 weeks, and Phase 2 populations usually have lower baseline weights and shorter observation periods. Still, the magnitude is interesting. At 12.3 percentage points placebo-adjusted after half a year, PF'3944 at the medium dose is roughly at semaglutide level, and with the planned 9.6 mg Phase 3 dose, the gap to tirzepatide could close to an acceptable margin.

For detailed comparison, see our GLP-1 agonist comparison as well as the more contextual single articles Semaglutide science 2026 and Tirzepatide science 2026 and the direct comparison of the triad in Retatrutide vs. Tirzepatide vs. Semaglutide.

Adherence: why monthly even matters

Obesity pharmacology is only an efficacy problem in the trial. In the real world, it is above all an adherence problem. Real-world data from US cohorts show adherence rates often below 50 percent after 12 months for semaglutide and tirzepatide patients. Weekly injections feel low-threshold, but 52 injections per year are simply 52 opportunities to break the protocol.

A monthly dose reduces injection frequency by a factor of four, from 52 to 12 injections per year. Practically this means:

• Travel and shift work are easier to combine with the therapy.
• Cold-chain logistics and pen procurement become less of an acute concern.
• The cognitive load of "did I already inject this week?" disappears.
• Pharmacy and telemedicine workflows could shift to quarterly instead of monthly orders.

From a healthcare system perspective, a true monthly shot can raise overall effectiveness over two years more than a weekly protocol that is two percentage points better but often discontinued after eight months. This calculation is the actual strategic lever Pfizer has in mind with the Metsera acquisition.

Competition: what Lilly and Novo could do in response

PF'3944 hits a landscape that has completely changed by May 2026:

• Eli Lilly received the first FDA approval for an oral GLP-1 tablet for weight loss in April 2026 with Orforglipron (Foundayo). Lilly also has the highly effective tirzepatide (Mounjaro/Zepbound) and is pushing retatrutide, a GLP-1/GIP/glucagon triple agonist, toward Phase 3.
• Novo Nordisk delivered positive Phase 2 data with amycretin, a dual GLP-1/amylin agonist, both as injection and tablet, and plans Phase 3 programs starting in 2026. A true monthly candidate of its own has not yet been publicly announced.

For both competitors, a Pfizer monthly shot is strategically uncomfortable because it occupies the only structural differentiation field besides efficacy: convenience. Realistic responses would be:

1. Own monthly or quarterly formulations based on existing molecules. Novo is reportedly working on a long-acting semaglutide line according to pipeline hints. Lilly has retatrutide, a molecule that in principle would be a candidate for albumin-binding optimization.
2. Adherence tools instead of pharmacology: smarter pens, longer weekly depots (e.g. every 14 days), digital reminder workflows.
3. Combination products: oral GLP-1 tablets plus monthly injection for maintenance. Pfizer itself has announced plans to further develop PF'3944 in combinations with other gut and appetite regulating hormones.

The real bottleneck for all three manufacturers in 2026 remains production. A successful monthly shot eases this chain: a patient consumes one quarter of the active ingredient volume of a classic weekly protocol per year at comparable per-injection volumes. So anyone who still has the 2024/2025 shortage in mind sees a second, often overlooked dimension of PF'3944 here.

Market implications for 2027 and 2028

If Phase 3 with the 9.6 mg dose delivers what Phase 2b suggests, in 2027 to 2028 we are likely to see the following:

• Market segmentation rather than displacement. The monthly shot primarily addresses the adherence segment, that is, users who fail or struggle with weekly protocols. Tirzepatide remains the choice for maximum efficacy; oral remains the low-threshold entry point.
• Reimbursement debates in the EU. If a monthly product demonstrably delivers better real-world outcomes, national payers could price this into health technology assessments. The UK's NICE and Germany (G-BA) are typically early movers here.
• Microdose and maintenance protocols. That gets its own section in a moment.
• Consolidation among smaller biotechs. Anyone with an ultra-long-acting platform is very likely to be acquired or licensed. The Metsera-Pfizer model is a template here.

EU approval pathway and timeline

PF'3944 is a US-centric development. For the EU, the likely path is:

1. 2026 (second half): start of several Phase 3 trials in parallel. Pfizer has announced 10 Phase 3 programs across its broader obesity portfolio, several of which will test PF'3944 in different populations and combinations.
2. 2027 to 2028: pivotal Phase 3 readouts. Some of these studies will very likely recruit in the EU, which strengthens the EMA data base.
3. Earliest 2029: EU approval submission via the centralized EMA procedure. The FDA submission is likely to come one or two quarters earlier.
4. 2030 plus: broad availability in EU pharmacies. Until then, semaglutide, tirzepatide and, from 2027, presumably retatrutide will continue to dominate.

This timeline is conservative and could be six to twelve months shorter via priority review or accelerated procedures. For EU users planning today in 2026, PF'3944 is in any case not a short-term option, but a strategic marker for the second half of the decade.

What does this mean for researchers and microdose users?

Microdosing protocols with semaglutide and tirzepatide have become established in the research and self-experimentation community over the past two years, mainly as a maintenance phase after classic weight loss or as metabolic optimization at physiological doses (see our GLP-1 microdosing protocol guide 2026). A few implications from the Pfizer data:

• Pharmacokinetic plausibility of the maintenance logic. If a monthly dose of 4.8 mg PF'3944 is sufficient to keep the GLP-1 receptor tone stable, that is a direct argument that even in microdose protocols the average plasma concentration, not the peak, carries the effect.
• Risk of loss of effect. Phase 2b showed no plateau effect between week 12 and 28. This argues against rapid tachyphylaxis at the receptor level, a finding that is also interesting for the discussion around microdose maintenance.
• Muscle loss remains the problem. As with all GLP-1 substances, a relevant share of weight loss comes from lean mass, depending on protein intake and training stimulus. For microdose users who want to remain in maintenance mode, the question of anabolic and regenerative companion protocols remains relevant.

For this area, we offer research materials from the GH secretagogue spectrum that are being investigated as add-ons in microdose protocols, including Sermorelin, CJC-1295, and Ipamorelin. These substances are sold exclusively for research purposes and are not GLP-1 competitors, but study objects for anabolic companion axes.

Limitations of the Phase 2b data

Before the enthusiasm, a sober look at the limits of the study is worthwhile:

• Sample size: 268 subjects is a solid Phase 2b size, but too small to reliably detect rare adverse events (pancreatitis, gallstones, retinal changes).
• Observation time: 28 weeks is less than half of the STEP-1 or SURMOUNT-1 duration. Statements about plateau, rebound, and long-term safety can only be derived from the 64-week data package.
• Concurrent lifestyle intervention. As with all GLP-1 studies, a standardized diet and exercise companion program is mandatory. How much of the weight loss is driven by pharmacology and how much by the study logic always remains an open question.
• No direct head-to-head data against semaglutide or tirzepatide. All comparisons are indirect and across different studies.
• Discontinuation rate of around 10 percent due to side effects is not dramatic, but higher than for tirzepatide in Phase 3. In Phase 3 with the higher 9.6 mg dose, this will need to be watched closely.
• Effects after stopping monthly therapy are not captured in the data published so far. The STEP-4-like rebound effects seen with semaglutide (two thirds of lost weight return within twelve months) are a realistic scenario for PF'3944 as well.

Pfizer's own stock reaction (briefly minus about 4 percent after the February data) reflects exactly this mix: solid data, but not so clearly superior that the competitive question would be settled.

What to expect on 6 June 2026

Pfizer and Metsera scientists will present the full data at the ADA Scientific Sessions in Chicago. Specifically, we expect:

• Weekly weight loss curves with standard deviations for all three arms.
• Subgroup analyses by BMI quartile, sex, and ethnic groups.
• Pharmacokinetic data for the monthly dose (especially C-trough and C-max).
• Data on HbA1c, lipids, blood pressure, and quality of life.
• First 64-week follow-up data on safety, if available by then.

This presentation will be the real fact check. Until then, all interpretations, including this article, should be read with the caveat that the topline press release is not the full picture.

Summary

With Phase 2b on PF'3944, Pfizer has delivered the first hard evidence that monthly GLP-1 dosing is biologically and clinically feasible. Efficacy at the medium 4.8 mg dose after 28 weeks is 12.3 percentage points placebo-adjusted, the safety profile is class-typical, and the planned 9.6 mg Phase 3 dose suggests significantly higher efficacy.

For the GLP-1 landscape, this does not mean the end of semaglutide or tirzepatide, but a segmentation along the axis of convenience and adherence. For EU users, PF'3944 is not relevant before 2029/2030. For research users and microdose communities, the study is an indirect validation point for the logic of flat, stable GLP-1 tone concepts. And for the competitors Novo and Lilly, the message is clear: in 2027, the battle will no longer be decided on efficacy alone, but also on frequency.

Further reading

• GLP-1 agonists compared for the big picture of the class.
• Semaglutide science 2026 for the current data on the market leader.
• Tirzepatide science 2026 on the dual incretin effect.
• Retatrutide vs. Tirzepatide vs. Semaglutide for the triple agonist context.
• GLP-1 microdosing protocol guide 2026 for maintenance strategies.
• Sermorelin/CJC/Ipamorelin companion protocols on anabolic axes for users who want to avoid muscle loss under GLP-1 protocols.

Sources:

• Pfizer, Pfizer's Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial
• BioPharma Dive, Pfizer dips on new data for obesity drug acquired in 10B deal
• Fierce Biotech, Pfizer's 10B monthly GLP-1 bet generates competitive weight loss in phase 2b
• MedCity News, Data for Pfizer's Monthly Injectable GLP-1 Drug Pave Way for Broad Phase 3 Plan in Obesity
• BioPharm International, Pfizer Phase IIb Data Support Monthly GLP-1 Dosing for Obesity
• Epocrates, Monthly GLP-1 injection demonstrates significant weight loss in phase 2b trial
• ClinicalTrials.gov listing for PF-08653944 (MET-097i), as of 4 February 2026

Frequently asked questions

---

This article reflects information available as of 11 May 2026. Clinical data and regulatory timelines can change at short notice. Detailed study results will be publicly discussed starting 6 June 2026 at the ADA Scientific Sessions.

All products sold by PeptidesDirect are intended exclusively for laboratory and research purposes. They are not intended for human consumption or therapeutic use. PF'3944 is not an approved medication and is not offered by PeptidesDirect.